Financials data is unavailable for this security.
View more
Year on year BioPharma Credit PLC 's revenues fell -37.78% from 218.14m to 135.73m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 182.31m to 108.45m, a -40.51% decrease.
| Gross margin | 81.85% |
|---|---|
| Net profit margin | 80.20% |
| Operating margin | 80.20% |
| Return on assets | 8.53% |
|---|---|
| Return on equity | 8.56% |
| Return on investment | 8.56% |
More ▼
Cash flow in USDView more
In 2023, BioPharma Credit PLC increased its cash reserves by 12.05%, or 14.53m. The company earned 123.18m from its operations for a Cash Flow Margin of 90.76%. In addition the company used 1.66m on investing activities and also paid 106.99m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.01 |
|---|---|
| Tangible book value per share | 1.01 |
More ▼
Balance sheet in USDView more
| Current ratio | 21.50 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 28.57% while earnings per share excluding extraordinary items fell by -38.04%. The positive trend in dividend payments is noteworthy since only some companies in the Investment Services industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 8.59% |
|---|---|
| Div growth rate (5 year) | 11.38% |
| Payout ratio (TTM) | 98.75% |
| EPS growth(5 years) | 3.15 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -37.44 |
More ▼
